An innovative technology company, which has developed a pioneering sterile iPad case for use in hospitals, has chosen Discovery Park in Sandwich as the base for its sales operations.
Futurenova is the company behind the FlipPad™, a new medical grade case for the iPad. Made from FDA (Food and Drug Administration) approved materials, the product is water and shock proof and, vitally, can be kept sterile with standard infection control sprays.
The case can be used in everything from operating theatres and infection control wards to general wards. It can be hung on a hospital bedrail and is sensitive enough to be used with surgeons’ gloves. The trailblazing case has even been granted a ‘made for iPad’ licence by Apple.
FlipPad™ is set to launch at the Infection Prevention Show, Liverpool on 28-30 September 2015. Following this, the product will be showcased at digital health show EHI Live in Birmingham (3-4 November 2015) and Innovate UK (9-10 November 2015).
Mike Casey, a former NHS director, founded Futurenova in April 2014. Mike said, “After several years developing the product in close consultation with the NHS, and extensive trials in leading hospitals such as Great Ormond Street, we’re excited to be launching FlipPad™ this month.
“Absolutely nothing like it currently exists and we anticipate it will make a real impact on infection control rates as well as having psychological outputs by connecting isolated patients to the outside world.
“From our base at Discovery Park, our sales team will now be able to get the FlipPad™ into the hands of those who need it. It’s a key stage for the company with a series of events serving as the platform for our official market launch.” FutureNova were able to successfully raise £500,000 in seed capital to help kick start the new venture and establish operations at Discovery Park.
NCL Innovation were hired as the Lead Advisor to FutureNova for the capital raise process, which included both equity and loan investments from Kent County Council (Expansion East Kent), the Low Carbon Innovation Fund and NCLs own investors. The company has also received grants from Innovate UK. FutureNova will now become part of the Discovery Park Incubator programme, run by NCL innovation. The programme aims to help accelerate new technology companies, such as FutureNova, safely through to commercialisation.
Speaking of Futurenova’s move to the leading science and technology park, Leasing Director Anna Stone, said: “We’re delighted to welcome Futurenova to Discovery Park, the latest in a growing number of innovative technology businesses now thriving on site. We wish them every success.
“Over the past three years Discovery Park has established itself as a hub for inventions and scientific discoveries, supported by an array of other businesses which together make science happen. And we look forward to Futurenova’s part in this story.” Jerry Biggs, CEO of NCL Innovation, said “FutureNova is an excellent example of a truly disruptive technology company, that has designed a product that can save the health industry vast amounts of expenditure whilst helping to mobilise clinical staff.
“The Discovery Park Incubator is an ideal location to take a product like this from concept through to commercial reality and NCL are delighted to be involved.”